New developments in the management of partial-onset epilepsy: role of brivaracetam

Giangennaro Coppola, Giulia Iapadre, Francesca Felicia Operto, Alberto Verrotti

Department of Medicine and Surgery, University of Salerno, Salerno, Italy

Abstract: Currently, a number of novel anticonvulsant drugs, the so-called third generation, are in various stages of development. Several of them are already available or in ongoing clinical trials. These new compounds should take advantage of new insights into the basic pathophysiology of epileptogenesis, drug metabolism and drug interactions. Many of them still need to be further evaluated mainly in real-world observational trials and registries. Among newer anticonvulsant drugs for partial-onset seizures (POSs), rufinamide, lacosamide, eslicarbazepine and perampanel are those new treatment options for which more substantial clinical evidence is currently available, both in adults and, to some extent, in children. Among the newest anticonvulsant drugs, brivaracetam, a high-affinity synaptic vesicle protein 2A ligand, reported to be 10- to 30-fold more potent than levetiracetam, is highly effective in a broad range of experimental models of focal and generalized seizures. Unlike levetiracetam, brivaracetam does not inhibit high-voltage Ca2+ channels and AMPA receptors and appears to inhibit neuronal voltage-gated sodium channels playing a role as a partial antagonist. Brivaracetam has a linear pharmacokinetic profile, is extensively metabolized and is excreted by urine (only 8%-11% unchanged). It does not seem to influence the pharmacokinetics of other antiepileptic drugs. It was approved in the European Union in January 2016 and in the US in February 2016 as an adjunctive therapy for the treatment of POS in patients older than 16 years of age. To date, its clinical efficacy as adjunctive antiepileptic treatment in adults with refractory POS at doses between 50 and 200 mg daily has been extensively assessed in two Phase IIb and four Phase III randomized controlled studies. Long-term extension studies show sustained efficacy of brivaracetam. Overall, the drug is generally well tolerated with only mild-to-moderate side effects. This is true also by intravenous route. Brivaracetam has not yet been evaluated as monotherapy or in comparison with other new anticonvulsant drugs.

Keywords: brivaracetam, partial-onset seizures, epilepsy, antiepileptic drugs, adjunctive therapy

Introduction to the classification of the partial-onset epileptic seizures

In the proposal for the revision of seizures and epilepsies by Engel et al.,1 the term “focal” was reintroduced instead of “partial”. Furthermore, this new scheme abandons the division of focal seizures into “simple” and “complex” forms. The reason given is that this “inappropriately created the impression that impairment of consciousness had certain mechanistic implications related to limbic system involvement”, and that “complex partial seizures” had been erroneously used as a synonym of “temporal lobe epilepsy”.

More recently, in the International League Against Epilepsy (ILAE) 2010 report, Berg et al.2 confirmed to remove the distinction between complex partial and simple partial, however, recognizing that impairment of consciousness/awareness or dyscognitive...
features and localization and progression of ictal events can be of primary importance in the evaluation of individual patients and “for specific purposes” (ie, driving license and medicolegal purposes).

For pragmatic reasons and to facilitate continuity with the 1981 classification of seizures, descriptors of focal seizures may be used “individually or in combination with other features depending on the purpose”.2

Following these criteria, “symptomatic temporal lobe epilepsy” should be turned into “temporal lobe epilepsy with seizure type (eg, dyscognitive and automotor) secondary to cortical dysplasia in the location (eg, left parahippocampal gyrus)”.

**Epidemiology of focal-onset seizures**

Many epidemiological studies have reported the distribution of seizures and/or syndromes according to the ILAE classification.

The majority of studies have reported a slight predominance of focal seizures (29.3%–63%) over generalized seizures (12.9%–48%).3,4 The percentage distribution of focal seizures varies with age.

Within the group of focal seizures, symptomatic forms slightly prevail at all ages; indeed, genetic forms usually occur in children but tend to sharply decrease in favor of seizures related to unknown or structural/metabolic causes throughout adolescence and young adulthood.

In keeping with this, idiopathic epilepsy with central–temporal spikes and Panayiotopoulos’ benign focal epilepsy syndrome are among the most common childhood-onset epilepsy syndromes. The incidence of this syndrome is estimated to be 10/100,000 children per year.5

The incidence of focal-onset seizures is even higher in developing countries, on account of the significant presence of environmental risk factors such as perinatal cerebral insults, brain injuries and various parasitic diseases (malaria, onchocerciasis, cysticercosis or toxocariasis).6,7

**Current management strategies of focal seizures**

In this field, more criteria have to be considered including age (children, adolescents or adults), etiology (idiopathic or cryptosymptomatic), comedication, comorbidity, family planning, etc.

**Focal seizures in genetic epilepsies**

Benign seizures with central–temporal spikes (BECTS) and benign childhood occipital epilepsy fall within this group. In practice, the first question is whether medication is required. In fact, seizures can be single (10% of BECTS) or occasional (≤3 per year) and are age dependent.

However, when one decides to treat them, they are typically sensitive to a drug monotherapy. In the past, there were different approaches across countries (valproic acid [VPA] or carbamazepine [CBZ] in Europe, phenytoin [PHT] or CBZ in the US, clobazam in Canada, etc.), in the absence of controlled studies.

Although controlled studies have been carried out only for sulthiame and gabapentin,8,9 both of these drugs have not reached the level A or B according to the ILAE quality criteria for initial monotherapy in BECTS.10 Indeed, worsening of reading, memory and attention have been reported.11

Currently, oxcarbazepine (OXC) and levetiracetam (LEV) appear to be the most promising new drugs.12,13 Furthermore, HLA-B*15:02 screening methods should also be considered for the prevention of carbamazepine-induced severe drug reactions.14

**Focal seizures in cryptogenic/ symptomatic epilepsy**

With respect to focal seizures in adulthood, CBZ, levetiracetam (LEV), PHT, and zonisamide (ZNS) are recognized as level A antiepileptic drug (AED), while VPA as level B AED; CBZ, LTG, OXC, lamotrigine (LTG), phenobarbital (PB), topiramate (TPM), and vigabatrin (VGB) are considered to be possibly efficacious/effective (level C), whereas clonazepam and primidone (PRM) are potentially efficacious/effective (level D).15

In elderly adults, on the contrary, gabapentin (GBP) and LTG are well-established therapies (level A); CBZ is possibly (level C) and TPM and VPA are potentially (level D) efficacious/effective as initial monotherapy. The National Institute of Health and Clinical Excellence (NICE) guidelines (2012) recommend CBZ and LTG as first-choice drugs in children, adolescents and adults with cryptogenic focal seizures. In the event that these two AEDs are unsuitable or not tolerated, they suggest LEV, OXC or VPA, provided that the cost of LEV diminishes by at least 50% compared to 2011.

NICE (2012) also recommends adding a second AED when monotherapy with a second AED is ineffective.

In the event of refractory focal seizures, NICE suggests CBZ, clobazam, GBP, LTG, LEV, OXC, VPA or TPM as additional medications if first-line treatments are ineffective or not tolerated. We should also pay special attention to the teratogenic or neurodevelopmental adverse effects of VPA.

Carbamazepine is the therapy of choice for children in most countries, whereas VPA is preferred for small children until the focal component of the epilepsy has been identified.17
Although CBZ, VPA, PHT and PB were found to be equally effective in newly diagnosed children,16 evident concerns undoubtedly exist regarding cognitive–behavioral effects, especially related to PB and PHT.19 OXC remains a possible alternative as initial monotherapy for children aged 4 years and older in view of its effectiveness, good tolerability and absence of drug interactions.18

Before starting treatment with CBZ or OXC, the opportunity to perform a HLA genetic profile to assess the potential risk of vasculitic reactions should be taken into consideration.14 Clobazam is considered a first-choice drug in some countries.19,20

For refractory cases, a second-line strategy includes five AEDs (LTG, TPM, GBP, OXC, LEV) for which there are placebo (PBO)-controlled randomized studies. The responder rates substantially overlap (range 21%–45%) with an average of 19% in the PBO groups.

The preference for a given drug is also based on the experience of the physician, on potential drug–drug interactions, on the need for rapid titration (LEV, GBP) in the presence of frequent seizures.

In infants, effective drugs are OXC (60 mg/kg is more effective than 10 mg/kg), lamotrigine and LEV compared to PBO.21,22

Emerging treatment options for partial-onset seizures (POSs)
The need for new AEDs, the so-called third generation, is based on the persistence, in a considerable number of patients of any age, of problems related to the second-generation drugs, which include the following: persistent drug resistance, dose-dependent idiosyncratic adverse effects and drug interactions.

Currently, a number of novel AEDs are in various stages of development. Several of them are already available or in ongoing clinical trials. These new compounds should take advantage of new insights into the basic pathophysiology of epileptogenesis, drug metabolism and drug interactions. Many of them still need to be further evaluated, mainly in real-world clinical observational trials and registries.

Among newer AEDs for POSs, rufinamide, lacosamide (LCM), eslicarbazepine (ESL), perampanel (PER) and brivaracetam (BRV) are briefly considered in the following sections in view of the fact that there is more substantial evidence on them both in adults and, to some extent, in children.

Rufinamid
Rufinamide is a compound not related to the existing AEDs, which inactivates the voltage-gated sodium channels (VGSCs). Rufinamide has been designated in Europe and the US by the Food and Drug Administration (FDA) as orphan drug for adjunctive treatment for Lennox–Gastaut syndrome with drop attacks. Perhaps, this recognition has hampered its broader assessment for focal seizures in both children and adults. However, there is increasing evidence for the effectiveness of Rufinamide (RUF) even in partial seizures, initially in adults with 28.2% responder rate23 and in children and adolescents with drug-resistant partial seizures.24–26 In these studies, the responder rate ranged between 42 and 46% of treated patients. Some of the data seem to suggest good efficacy against seizures originating in the frontal lobe27 and those secondary to neuronal migration disorders.28

Eslicarbazepine
ESL is a third-generation AED structurally related to CBZ and OXC, approved by European Medicines Agency (EMA) in 2009 and by FDA in 2013 as an adjunctive drug in the treatment of focal-onset seizures with or without secondary generalization in adults. ESL works by blocking the VGSCs. A responder rate between 17 and 43% was seen in four Phase III randomized controlled studies in subjects aged ≥18 or 16 years with refractory POSs.29,30

ESL was significantly more effective than PBO at the dose of 1,200 mg once daily. The efficacy of adjunctive ESL acetate was maintained in the longer term (up to 2 years) according to the results of extension studies.31–33 Overall, these medications were well tolerated and safe, most adverse events (AEs) being of mild-to-moderate severity. More recently, ESL acetate was licensed as monotherapy for POS in adults in the US and Europe based on two randomized, double-blind, conversion-to-monotherapy Phase III trials (1,200 or 1,600 mg once daily) in patients with uncontrolled partial epilepsy.34

In addition, an overnight switch from twice-daily OXC to once-daily ESL in patients with partial-onset epilepsy resulted in improvement in side effects, alertness and quality of life.35

Although ESL is currently not allowed under 18 years of age, a favorable pharmacokinetic, tolerability and efficacy profile has been reported in preliminary studies in children,36,37 thus suggesting that the drug may be useful in the management of epileptic children.

Lacosamide
LCM, a third-generation AED, is a functionalized amino acid first approved in 2008 as add-on drug for refractory POS in adults older than 17 years and then approved in 2014 as monotherapy for POS by FDA (US). Unlike traditional
sodium channel blockers affecting fast inactivation, LCM selectively enhances sodium channel slow inactivation. As adjunctive drug for focal-onset seizures, LCM in three randomized controlled, dose-ranging trials (200–600 mg/day) including 1,311 participants, led to a significant seizure reduction as well as seizure freedom compared to PBO over a period ranging from 24 to 26 weeks. Overall, LCM was well tolerated, although higher doses of LCM were associated with a higher incidence of AEs. More recently, LCM resulted to be efficacious as adjunctive treatment or conversion monotherapy, in temporal lobe epilepsy regardless of the presence of hippocampal sclerosis, at the daily dose of 200–400 mg in adult patients.\(^\text{38}\)

Furthermore, LCM may work better as first add-on than later adjunctive treatment for uncontrolled POS.\(^\text{39,40}\) Several recent experiences suggest that LCM monotherapy, either as first-line or after conversion, may be a valuable option, even in the long term, for patients with focal epilepsy.\(^\text{41–43}\) The most common treatment-emergent adverse effects (TEAEs) with this drug are dizziness, headache and somnolence;\(^\text{39}\) nonetheless, planned reduction in concomitant AEDs during LCM initiation and the use of non-sodium channel blockers agents only are associated with a reduced risk of TEAEs.\(^\text{44}\) Currently, the lack of head-to-head comparisons with other AEDs prevents an exact positioning of LCM in the therapeutic schedule of focal seizures.

**Perampanel**

PER is an AMPA receptor antagonist first licensed for the treatment of focal seizures with or without secondary generalization in adults and children 12 years of age and over, following the completion of a number of dose-ranging, PBO-controlled trials, in which it was used as adjunctive therapy.\(^\text{45}\) These studies compared 4, 8 and 12 mg daily doses of PER at bedtime with PBO. More recently, PER has been approved as add-on medication for primary generalized tonic-clonic seizures epilepsy.

In most clinical studies, the responder rate was 25%–38% and the most effective daily doses were 8–12 mg. However, a number of patients may significantly improve also with 4 mg/day.

Seizure freedom was reported in 2.6%–6.4% of patients with 8–12 mg of PER daily.

Overall, PER was safe, well tolerated and effective. The most frequent dose-correlated TEAEs were sleepiness, behavioral problems and dizziness. In addition, PER does not alter cognition significantly.\(^\text{46}\)

**Epilepsy treatment options other than drugs**

Although many children and adults with epilepsy respond more or less quickly to drug medications, ∼25%–30% of them develop drug resistance, often combined with worrisome systemic and/or cognitive–behavioral adverse side effects.

The next step is then to consider surgical approach that is especially suitable for well-localized epileptogenic brain lesions. However, when they are present in eloquent areas (eg, motor, language or memory) or in the event of multifocal epilepsies, surgery is not easily applicable. For this reason, only ∼5% of patients are candidates for epilepsy surgery, to date.

Temporal and extratemporal lobe surgeries most frequently include hippocampal sclerosis and/or focal cortical dysplasias, elastic lesions and cortical malformations, brain tumors, vascular lesions and hypothalamic hamartomas, albeit with differences concerning clinical approach and neuropsychological outcome between adults and children. Surgical resolution of epilepsy can reach up to 80%–90% of patients, and it is now recommended as early as possible in specific conditions.

When surgical treatment is not applicable for different reasons, epileptologists should consider non-pharmacological approaches including diet and neurostimulation.

The former includes different ketogenic and less ketogenic regimens such as the classic 4:1 ketogenic diet, the modified Atkins diet (MAD), the low glycemic index treatment (LGIT) and the medium-chain triglyceride (MCT) diet, which are feasible not only in childhood but also in adults.\(^\text{47}\) If diets are ineffective, neurostimulation is often the next viable option. Beyond the well-known vagus nerve stimulation (VNS),\(^\text{48}\) electrical stimulation to suppress seizure activity can be provided directly to the brain by means of deep brain stimulation (DBS; eg, thalamic nuclei) or the brain cortex, using a cortical device which is “responsive” as it detects seizure activity and subsequently disrupts it via electrical stimulation to the cortex (responsive neurostimulator, NRS).\(^\text{49}\) Finally, transcranial magnetic stimulation (TMS) is a method of stimulation using magnetic fields rather than electricity to reduce seizure frequency.\(^\text{50}\)

**Brivaracetam**

The pharmacokinetic/dynamic features, as well as the clinical efficacy and tolerability of BRV, are presented and discussed in the following sections.
Mode of action

BRV is a selective, high-affinity and reversible SV2A ligand. SV2A is a glycoprotein located in the presynaptic membrane and ubiquitously expressed in the brain, which is involved in the modulation of synaptic vesicle exocytosis and neurotransmitter release. In particular, SV2A seems to have an important role in epileptogenesis, as reported for transgenic mice in which SV2A deficiency led to increased seizure vulnerability. The exact mechanism whereby ligand binding to SV2A reduces seizure susceptibility is still unclear. Nevertheless, several attempts have been made in this way.

Rationally designed to have a higher affinity and selectivity for SV2A with respect to its analog LEV, BRV shows a 15- to 30-fold higher binding affinity to SV2A than LEV, demonstrated in both animal and human brains.

BRV also shows high binding selectivity. In fact, in vitro experiments reported that at the concentration of 10 μM (more than a 100-fold above its affinity for SV2A), it did not bind, activate or inhibit a panel of 55 other receptors, channels and enzymes potentially involved in epilepsy. In addition, results from SV2A knockout mice showed that up to the concentration of 600 nM (the highest concentration tested), [3H]BRV only labeled SV2A proteins. A recent study has revealed that BRV, similar to LEV, enters into recycling synaptic vesicles, producing a frequency-dependent decrease in synaptic transmission at 100-fold lower concentrations than LEV. Moreover, BRV was more effective than LEV in slowing synaptic vesicle mobilization.

In addition, BRV displays inhibitory activity on VGSCs, which, however, seems not to represent a relevant mechanism involved in its anticonvulsant properties. In fact, a study assessing BRV pharmacology on VGSCs in different cell systems, and evaluating the efficacy of BRV in reducing sustained repetitive firing (SRF) in comparison to carbamazepine, revealed a substantial lack of effect of BRV on SRF in neurons, suggesting that none of its antiepileptic effects are mediated by VGSC blockade.

Pharmacokinetics of BRV

The pharmacokinetic properties of BRV have been studied extensively. Clinical trials have been conducted in adult healthy volunteers, in the elderly, in patients with epilepsy and in those with hepatic or renal impairment, revealing only minor differences not requiring any dose adjustment. In particular, in healthy adults, BRV exhibited a linear pharmacokinetic profile over a broad range of doses (single doses: 10–1,400 mg; multiple doses: 200–800 mg daily) with low interindividual variability. After oral administration, BRV was quickly and almost completely absorbed throughout the gastrointestinal tract with a median Tmax of ~1–2 h. Cmax showed a dose-proportional trend from 10 to 1,400 mg, while area under the curve (AUC) profile maintained dose linearity until 600 mg. Absorption of BRV was not affected by food ingestion: a high-fat meal had the effect of delaying Tmax (3 h) and decreasing Cmax, but caused no modification of AUC. Its distribution volume (0.6 L/kg) was slightly lower than total body water, and a small proportion (~20%) was weakly bound to plasma proteins. Thanks to its ability to cross mucous membranes, BRV saliva and plasma levels were closely correlated, suggesting that saliva could be a suitable sample for monitoring BRV plasma concentrations when blood samples are unavailable.

BRV has a fast onset of action; pharmacologic peak activity and peak plasma levels occur simultaneously, after a single oral dose of the drug. In contrast, LEV maximum plasma activity follows maximum plasma concentrations by almost 1 h. This remarkable property derives from its lipophilicity, which enables BRV to optimally penetrate into the brain. In fact, as reported for rodents, BRV shows a faster entry into the brain than LEV and a faster onset of action against seizure in audiogenic mice, suggesting that BRV may offer benefits in the treatment of acute seizures.

A small fraction of the dose (5%–8%) is excreted unchanged in the urine with a large amount of inactive metabolites (acid, hydroxy and hydroxy acid derivatives). BRV is extensively metabolized throughout two main metabolic pathways, including hepatic hydrolysis of the acetamide group and hydroxylation by cytochrome (CYP) P450 2C19. Renal clearance of the parent drug is low (0.04 per min/kg) and >95% of the dose is eliminated by renal excretion within 72 h. BRV plasma half-life is ~7–8 h.

Patients with inactive mutations of CYP2C19 show only minor reduction (29%) in BRV clearance, which is probably not clinically significant. Thus, individuals with CYP2C19 genetic polymorphisms do not require any dose adjustment.

In patients with severe renal impairment, defined as creatinine clearance >30 mL/min, major exposure (>20%) to BRV has been reported, in addition to increased levels of its metabolites. Nevertheless, dose reduction is not required due to the inactivity and low toxicity of BRV metabolites.

In individuals with hepatic impairment, 25%–35% reduction in BRV clearance and, therefore, increase in exposure to
BRV with a prolonged half-life to 14–17 h are reported, with a consequent need for reduction by one-third of the maximum daily dose of the drug in this group of patients.65

**Comparative efficacy, safety and tolerability of BRV**

**Efficacy**

BRV as adjunctive therapy: Clinical efficacy of BRV as adjunctive antiepileptic treatment has been extensively assessed in six randomized controlled trials (RCTs): two Phase IIb66–67 and four Phase III studies,68–70 including a total of 2,393 adult patients (aged 16–80 years) affected by refractory POS, and the results are reported in Table 1.

**Phase IIb studies**

In the first trial,66 210 patients aged 16–65 years, with refractory POS, were randomized to PBO, BRV 5, 20 or 50 mg/day b.i.d., without up-titration, for a treatment period of 7 weeks. Statistically significant percentage reductions over PBO in POS frequency/week were reported for the 50 mg/day group (22.1%, P=0.004), but not for the 5 or 20 mg/day group. Similarly, the percentage reduction from baseline in weekly POS frequency during the treatment period was significant in the 50 mg/day group (28.7%, P<0.001) and in the 20 mg/day group (22.5%, P=0.0014), but not in the 5 mg/day group. Fifty percent responder rates from baseline in terms of weekly POS frequency were significant for all three BRV groups (5 mg/day 32.0%, P=0.047; 20 mg/day 44.2%, P=0.0002; 50 mg/day 55.8%, P<0.0001). Percentages of seizure freedom achieved by participants during the 7-week treatment period were not statistically significant for any of the BRV groups: 1.9% for PBO, 8.0% for BRV 5, 7.7% for BRV 20 and 7.7% for BRV 50. BRV proved to be effective as adjunctive treatment in adults with POS, showing a dose-related efficacy profile for doses ranging from 5 to 50 mg/day.

The second study67 included 157 adult patients with similar characteristics at enrollment, who were randomized to receive PBO, BRV 50 or 150 mg/day b.i.d., for a 3-week up-titration period, followed by a 7-week maintenance period. Reduction rate in seizure frequency/week over PBO during the entire treatment period was not statistically significant for any group. Percentage reduction from baseline in weekly POS frequency during the maintenance period was significant for 50 mg/day (38.2%, P=0.017), but not for 150 mg/day versus PBO. Fifty percent responder rates from baseline during the whole treatment period were significant for 50 mg/day (35.8%, P=0.038), but not for 150 mg/day.

**Table 1** Efficacy end points from Phase II and Phase III RCTs

<table>
<thead>
<tr>
<th>Study</th>
<th>ITT population</th>
<th>Up-titration period</th>
<th>Treatment dose (mg/day) and number of patients (n)</th>
<th>≥50% responder rate</th>
<th>Seizure freedom (%)</th>
<th>Seizure reductions over PBO/week (%)</th>
<th>Seizure reductions over PBO/28 days (%)</th>
<th>Median% reduction from baseline in seizure frequency/week</th>
</tr>
</thead>
<tbody>
<tr>
<td>French et al66</td>
<td>208</td>
<td>No</td>
<td>PBO (n=54)</td>
<td>16.7</td>
<td>1.9 (NS)</td>
<td>–</td>
<td>–</td>
<td>21.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>BRV 5 (n=50)</td>
<td>32.0, P&lt;0.047</td>
<td>8.0 (NS)</td>
<td>9.8 (NS)</td>
<td>–</td>
<td>29.9 (NS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>BRV 20 (n=52)</td>
<td>44.2, P=0.0002</td>
<td>7.7 (NS)</td>
<td>14.9 (NS)</td>
<td>–</td>
<td>42.6, P=0.0014</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>BRV 50 (n=52)</td>
<td>55.8, P&lt;0.0001</td>
<td>7.7 (NS)</td>
<td>22.1, P&lt;0.004</td>
<td>–</td>
<td>53.1, P&lt;0.001</td>
</tr>
<tr>
<td>Van</td>
<td>157</td>
<td>Yes</td>
<td>PBO (n=52)</td>
<td>23.1</td>
<td>1.9</td>
<td>–</td>
<td>–</td>
<td>18.9</td>
</tr>
<tr>
<td>Paesschen et al68</td>
<td></td>
<td></td>
<td>BRV 50 (n=53)</td>
<td>39.6 (NS)</td>
<td>9.4</td>
<td>17.7, P=0.026</td>
<td>–</td>
<td>38.2, P&lt;0.017</td>
</tr>
<tr>
<td>Kwan et al49</td>
<td>480</td>
<td>No</td>
<td>BRV 150 (n=52)</td>
<td>33.3 (NS)</td>
<td>5.8</td>
<td>16.3, P=0.043</td>
<td>–</td>
<td>30.0 (NS)</td>
</tr>
<tr>
<td>Biton et al50</td>
<td>396</td>
<td>No</td>
<td>BRV 20–150 (n=359)</td>
<td>30.3, P&lt;0.006</td>
<td>1.5 (NS)</td>
<td>7.3 (NS)</td>
<td>–</td>
<td>26.9 (NS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO (n=98)</td>
<td>16.7 (NS)</td>
<td>0</td>
<td>–</td>
<td>–</td>
<td>17.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>BRV 5 (n=97)</td>
<td>21.9 (NS)</td>
<td>1.1 (NS)</td>
<td>0.9 (NS)</td>
<td>2.6 (NS)</td>
<td>20.0 (NS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>BRV 20 (n=100)</td>
<td>23.2 (NS)</td>
<td>1.0 (NS)</td>
<td>4.1 (NS)</td>
<td>8.7 (NS)</td>
<td>22.5 (NS)</td>
</tr>
<tr>
<td>Ryelin et al51</td>
<td>398</td>
<td>No</td>
<td>BRV 50 (n=101)</td>
<td>32.7, P&lt;0.008</td>
<td>4</td>
<td>12.8, P=0.025</td>
<td>22.0, P=0.004</td>
<td>30.5, P=0.003</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO (n=100)</td>
<td>20.0 (NS)</td>
<td>0</td>
<td>–</td>
<td>–</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>BRV 20 (n=99)</td>
<td>27.3 (NS)</td>
<td>2</td>
<td>6.8 (NS)</td>
<td>10.2 (NS)</td>
<td>30.0, P=0.019</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>BRV 50 (n=99)</td>
<td>27.3 (NS)</td>
<td>0</td>
<td>6.5 (NS)</td>
<td>9.2 (NS)</td>
<td>26.8 (NS)</td>
</tr>
<tr>
<td>Klein et al51</td>
<td>760</td>
<td>No</td>
<td>BRV 100 (n=100)</td>
<td>36.0, P&lt;0.023</td>
<td>4</td>
<td>11.7, P&lt;0.037</td>
<td>20.5, P&lt;0.010</td>
<td>32.5, P&lt;0.004</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO (n=259)</td>
<td>21.6</td>
<td>0.8</td>
<td>–</td>
<td>–</td>
<td>17.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>BRV 100 (n=252)</td>
<td>38.9, P&lt;0.001</td>
<td>5.2, P=0.003</td>
<td>–</td>
<td>22.8, P&lt;0.001</td>
<td>37.2, P&lt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>BRV 200 (n=249)</td>
<td>37.8, P&lt;0.001</td>
<td>4.0, P=0.019</td>
<td>–</td>
<td>23.2, P&lt;0.001</td>
<td>35.6, P&lt;0.001</td>
</tr>
</tbody>
</table>

Abbreviations: BRV, brivaracetam; ITT, intent-to-treat; NS, not significant; PBO, placebo; RCTs, randomized controlled trials.
Phase III studies

Four randomized, double-blind, PBO-controlled Phase III trials\textsuperscript{68–71} including a total of \textgreater 2,000 adult patients have been conducted to evaluate BRV as add-on treatment in refractory POS. In particular, one flexible dose and three fixed-dose studies are available.\textsuperscript{68–71}

The flexible-dose trial\textsuperscript{68} was designed to assess safety and tolerability of BRV as primary outcome, efficacy being a secondary objective. The study included 480 adult patients, aged 16–70 years, affected by untreated epilepsy (431 had focal epilepsy and 49 had primary generalized epilepsy). After a prospective 4-week baseline, patients were randomized to b.i.d. BRV or PBO. BRV was introduced at the daily dose of 20 mg and increased up to 50, 100 or 150 mg, at intervals of 2 weeks, based on the investigator’s assessment of efficacy and tolerability. The dose-finding period lasted for 8 weeks, followed by an 8-week dose maintenance period, for the whole treatment period of 16 weeks. Twenty percent of patients received concomitant LEV. The final dose of 100–150 mg/day was given to 71.6% of BRV-treated patients, while 20–50 mg/day dose was administered to the other patients. Ninety percent of BRV-treated patients and 91.7% of PBO-receiving patients were able to complete the study. In patients with focal epilepsy, both the baseline-adjusted percent reduction in BRV over PBO group and the median percent reduction in seizure frequency/week during the treatment period were not statistically significant. On the other hand, \textgeq 50% responder rate was significant for BRV (30.3% BRV versus 16.7% PBO, \(P=0.006\)). In patients with primary generalized epilepsy, the median reduction rate from baseline in weekly seizure frequency was 42.6% versus 20.7%, and the \textgeq 50% responder rate was 44.4% versus 15.4% in BRV-treated and PBO-treated patients, respectively. In terms of baseline-adjusted percent reduction in focal seizure frequency/week during the treatment period, better results were reported for patients in the BRV group, not receiving concomitant LEV, than for patients using LEV concomitantly. Differences in achieving seizure freedom were not significant between the two groups (1.5% BRV group, compared with 0% PBO group).

The three fixed-dose studies were all similarly designed. The first of these,\textsuperscript{69} included 400 adult patients aged 16–70 years, affected by drug-resistant POS. They were recruited in Australia, Brazil, Canada, Mexico and the US. Concomitant LEV was used by 20% of patients. After an 8-week prospective baseline period, patients were randomized to receive PBO or BRV (5, 20 or 50 mg/day) during a 12-week treatment period. Approximately 91.2% of patients completed the study. Percent reduction in POS frequency/wk over PBO was significant for BRV 50 mg/day (12.8%; \(P=0.025\)), but not for BRV 20 mg/day (4.1%) or for BRV 5 mg/day (0.9%). The percent reduction over PBO was statistically significant in terms of baseline-adjusted seizure frequency/28 days for BRV 50 mg/day (22.0%; \(P=0.004\)) but not for the other BRV groups. In the BRV 50 mg/day group, statistical significance was also reported for the \textgeq 50% responder rate (BRV 32.7% versus PBO 16.7%; \(P=0.008\)) and median percent reduction from baseline in seizure frequency/week (BRV 30.5% versus PBO 17.8%; \(P=0.003\)). Good results, in terms of efficacy, were reported for both patients who had already used LEV (BRV 20 and 50 mg/day groups) and patients who were LEV naive (all doses), while the efficacy in patients using concomitant LEV was lower, suggesting a limited effect of BRV when it is used combined with LEV.

The second study\textsuperscript{70} included 399 adults from Europe and India, with refractory POS, aged 16–70 years. After an 8-week prospective baseline, patients were randomized to receive PBO or 20, 50 and 100 mg/day BRV during a 12-week period. Concomitant use of LEV was reported in 20% of randomized patients. Percent reduction over PBO in baseline-adjusted seizure frequency/week was not statistically significant for BRV 20 and 50 mg/day dose (6.8 and 6.5%, respectively), while it was statistically significant for BRV 100 mg/day (11.7%; \(P=0.037\)). On the contrary, a significant median percent reduction from baseline in seizure frequency/week was seen for BRV 20 (30.0%; \(P=0.019\)) and for BRV 100 (32.5%; \(P=0.004\)), but not for BRV 50 mg/day, compared with PBO. In terms of \textgeq 50% responder rates, a statistical significance was observed only in the BRV 100 mg/day group (36.0%; \(P=0.023\)).

The third study\textsuperscript{71} was conducted in a very large population of 768 adults with uncontrolled POS despite treatment with 1–2 antiepileptic drugs. After an 8-week prospective baseline period, patients were randomized to PBO, BRV 100 mg/day or BRV 200 mg/day. Treatment period lasted for 12 weeks. Percent reduction over PBO in 28-day adjusted seizure frequency was statistically significant for both BRV 100 mg/day (22.8%; \(P<0.001\)) and BRV 200 mg/day (23.2%; \(P<0.001\)). Similarly, also the \textgeq 50% responder rates were statistically significant for both the BRV groups (38.9%; \(P<0.001\) for BRV 100 mg/day and 37.8% for BRV 200 mg/day, respectively) compared with 21.6% for PBO. Add-on BRV was effective in reducing POS in adults who did not use concomitant LEV and led to significantly higher seizure-free rates (5.2 and 4.0%, respectively) than PBO (0.8%).
Interestingly, no dose-dependent effect was found between the dosage regimen of 100 and 200 mg/day.

To summarize, the primary efficacy end point in all Phase II and Phase III fixed-dose studies was the reduction rate in seizure frequency over PBO. Concerning to this, BRV was found to be efficacious at 50 mg/day dose, but not at 20 or 5 mg/day dose.66–69 Two studies failed to show efficacy for BRV 50 mg/day dose.67,70 Moreover, statistically significant PBO-adjusted seizure reduction was found for BRV 100 mg/day dose in two Phase III trials,70,71 and for BRV daily dose of 200 mg.71 BRV 150 mg did not meet the primary efficacy outcome when administered in the second Phase II study.67 Median percent baseline-adjusted seizure reduction and ≥50% responder rates, considered as secondary endpoints, were achieved at the dose of BRV 5, 20 and 50 mg/day in the first Phase II study70 and at the dose of 50 mg,67,69 but not 150 mg/day in the second Phase II study.67 Good results were reported also for the daily dose of 10070,71 and 200 mg.71

Meta-analyses

To date, three meta-analyses72–74 have systematically assessed the efficacy and safety of BRV compared with PBO as adjunctive therapy for adults with refractory POS. In the first two articles,72,73 five RCTs were reviewed, including a total of 1,639 patients; 50% responder rates and seizure-free rates were analyzed as end points for evaluating BRV efficacy. Fifty percent responder rates among patients treated with BRV 20, 50 or 100 mg/day were significantly higher than among patients receiving PBO (20 mg: relative risk [RR] = 1.63, 95% CI = 1.18–2.27, P = 0.003; 50 mg: RR = 2.00, 95% CI = 1.50–2.66, P < 0.00001; 100 mg: RR = 1.80, 95% CI = 1.12–2.88, P = 0.01), while no statistically significant difference emerged from the comparison between PBO and the BRV daily dosage of 5 or 150 mg. In terms of seizure freedom, BRV was found to be significantly effective, in all BRV groups regardless of dosage, compared to PBO.72 In the most recent meta-analysis74 including six RCTs for a total of 2,399 patients, BRV efficacy was evaluated in terms of ≥50% responder rates and seizure-free rates. Compared to PBO, BRV was more efficacious in decreasing seizure frequency by 50% or more at BRV daily dose ranging from 20 to 200 mg, suggesting a dose-related effect up to the dosage of 50 mg daily. In addition, the subanalysis by LEV status showed greater efficacy of BRV in LEV-naive patients, although larger studies are required to confirm this finding.74

In conclusion, overall data demonstrated that BRV is effective, at the dosage of 20–200 mg/day, in reducing seizure frequency in adult patients with refractory partial-onset epilepsy.

Long-term extension studies

Patients who completed the two Phase II studies,66,67 the four (three fixed69–71 and one flexible dose68) Phase III studies and the Phase III intravenous (IV) study73 were offered to enter one of three long-term follow-up (LTFU) studies, to assess safety, tolerability and seizure control during long-term treatment with adjunctive BRV. Out of 2,186 BRV-treated patients, 93.8% (2,051) completed core studies and entered LTFU. Some of them continued to receive BRV for >8 years. Enrolled patients received a flexible dose of BRV add-on treatment, starting from the same daily dosage they received at the end of the previous study or 150 mg, up to a maximum of 200 mg. Data were analyzed until January 2014. At the clinical cutoff date, BRV exposure was up to 96 months for one LTFU trial. As reported in a pooled analysis,70 the overall median baseline-adjusted reduction in POS/28 days was 48.8%, which increased from 43.1% for the 1,834 patients who received BRV during a 1–3-month period, to 77% for the 540 patients receiving BRV for 58–60 months. Similarly, the percentage of patients with a ≥50% response increased over time, from 43.5% for 1–3 months to 71.0% for 58–60 months. Seizure-free rates for the first 6, 12, 24 and 60 months of BRV exposure were 4.9, 4.2, 3.0 and 3.3%, respectively. In conclusion, these LTFU studies strongly support the efficacy of BRV antiepileptic activity, also for prolonged periods.

Safety and tolerability

BRV as adjunctive therapy

Safety and tolerability of oral administration of BRV as adjunctive treatment in adults with uncontrolled focal epilepsy have been carefully evaluated in six RCTs,66–71 and the results are given in Table 2.

At the recommended dosage range of 50–200 mg/day, BRV was generally well tolerated in adult patients (aged ≥16 years). Most AEs were mild to moderate and related to the central nervous system.

As reported in a recent meta-analysis,74 including all six RCTs,66–71 BRV showed an overall safety profile, as confirmed by treatment withdrawal rates, which was similar to PBO across all BRV doses. The most frequent TEAEs and their incidence rates among patients receiving BRV were 12.4% for somnolence, 10.4% for headache, 9.6% for dizziness, 7.7% for fatigue, 4.9% for nausea, 4.2% for nasopharyngitis, 2.8% for irritability, 2.5% for insomnia, 2.0% for anxiety.
<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment dose and number of patients</th>
<th>At least one TEAE (%)</th>
<th>Drug-related AEs (%)</th>
<th>Somnolence (%)</th>
<th>Headache (%)</th>
<th>Dizziness (%)</th>
<th>Fatigue (%)</th>
<th>Psychiatric TEAEs (%)</th>
<th>SAEs (%)</th>
<th>Deaths</th>
<th>Possibly drug-related deaths</th>
<th>TEAEs-related withdrawal rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>French et al&lt;sup&gt;64&lt;/sup&gt; (Phase II)</td>
<td>PBO (54)</td>
<td>53.7</td>
<td>22.2</td>
<td>7.4</td>
<td>7.4</td>
<td>5.6</td>
<td>3.7</td>
<td>–</td>
<td>0</td>
<td>0</td>
<td>–</td>
<td>3.7</td>
</tr>
<tr>
<td></td>
<td>BRV 5 (50)</td>
<td>52</td>
<td>14</td>
<td>2</td>
<td>8</td>
<td>2</td>
<td>0</td>
<td>–</td>
<td>0</td>
<td>0</td>
<td>–</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>BRV 20 (52)</td>
<td>55.8</td>
<td>19.2</td>
<td>5.8</td>
<td>3.8</td>
<td>0</td>
<td>3.8</td>
<td>–</td>
<td>1.9</td>
<td>0</td>
<td>–</td>
<td>1.9</td>
</tr>
<tr>
<td></td>
<td>BRV 50 (52)</td>
<td>53.8</td>
<td>23.1</td>
<td>5.8</td>
<td>1.9</td>
<td>7.7</td>
<td>5.8</td>
<td>–</td>
<td>0</td>
<td>0</td>
<td>–</td>
<td>0</td>
</tr>
<tr>
<td>Van Paesschen et al&lt;sup&gt;67&lt;/sup&gt; (Phase II)</td>
<td>PBO (52)</td>
<td>71.2</td>
<td>42.3</td>
<td>5.8</td>
<td>7.7</td>
<td>5.8</td>
<td>7.7</td>
<td>21.2</td>
<td>7.7</td>
<td>0</td>
<td>–</td>
<td>1.9</td>
</tr>
<tr>
<td></td>
<td>BRV 50 (53)</td>
<td>67.9</td>
<td>41.5</td>
<td>9.4</td>
<td>15.1</td>
<td>3.8</td>
<td>13.2</td>
<td>13.2</td>
<td>1.9</td>
<td>0</td>
<td>–</td>
<td>3.8</td>
</tr>
<tr>
<td></td>
<td>BRV 150 (52)</td>
<td>67.3</td>
<td>36.5</td>
<td>5.8</td>
<td>7.7</td>
<td>9.6</td>
<td>5.8</td>
<td>11.5</td>
<td>3.8</td>
<td>0</td>
<td>–</td>
<td>3.8</td>
</tr>
<tr>
<td>Kwan et al&lt;sup&gt;68&lt;/sup&gt; (Phase III)</td>
<td>PBO (121)</td>
<td>–</td>
<td>–</td>
<td>7.1</td>
<td>19.8</td>
<td>5.8</td>
<td>4.1</td>
<td>11.6</td>
<td>7.4</td>
<td>0</td>
<td>–</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>BRV 20–150 (359)</td>
<td>66</td>
<td>–</td>
<td>11.1</td>
<td>14.2</td>
<td>8.6</td>
<td>7.8</td>
<td>12.3</td>
<td>5.3</td>
<td>0</td>
<td>0</td>
<td>6.1</td>
</tr>
<tr>
<td>Biton et al&lt;sup&gt;69&lt;/sup&gt; (Phase III)</td>
<td>PBO (98)</td>
<td>–</td>
<td>–</td>
<td>7.1</td>
<td>14.3</td>
<td>9.2</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>–</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>BRV 5 (97)</td>
<td>71.1</td>
<td>–</td>
<td>14.4</td>
<td>11.3</td>
<td>12.4</td>
<td>3.1</td>
<td>5.2</td>
<td>1</td>
<td>0</td>
<td>–</td>
<td>8.2</td>
</tr>
<tr>
<td></td>
<td>BRV 20 (100)</td>
<td>79</td>
<td>–</td>
<td>14</td>
<td>6</td>
<td>14</td>
<td>13</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>BRV 50 (101)</td>
<td>75.2</td>
<td>–</td>
<td>16.8</td>
<td>12.9</td>
<td>15.8</td>
<td>9.9</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>5.9</td>
</tr>
<tr>
<td>Ryvlin et al&lt;sup&gt;70&lt;/sup&gt; (Phase III)</td>
<td>PBO (100)</td>
<td>53</td>
<td>31</td>
<td>6</td>
<td>9</td>
<td>5</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>BRV 20 (99)</td>
<td>56.6</td>
<td>23.2</td>
<td>8.1</td>
<td>14.1</td>
<td>5.1</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>–</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>BRV 50 (99)</td>
<td>62.6</td>
<td>37.4</td>
<td>6.1</td>
<td>18.2</td>
<td>7.1</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>0</td>
<td>–</td>
<td>5.1</td>
</tr>
<tr>
<td></td>
<td>BRV 100 (100)</td>
<td>63</td>
<td>42</td>
<td>8</td>
<td>9</td>
<td>5</td>
<td>8</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>–</td>
<td>5</td>
</tr>
<tr>
<td>Klein et al&lt;sup&gt;71&lt;/sup&gt; (Phase III)</td>
<td>PBO (259)</td>
<td>59.4</td>
<td>22.2</td>
<td>7.7</td>
<td>8.4</td>
<td>5</td>
<td>3.8</td>
<td>7.7</td>
<td>3.4</td>
<td>0</td>
<td>–</td>
<td>3.8</td>
</tr>
<tr>
<td></td>
<td>BRV 100 (252)</td>
<td>68.4</td>
<td>38.3</td>
<td>19.4</td>
<td>6.7</td>
<td>10.3</td>
<td>7.5</td>
<td>10.3</td>
<td>3.2</td>
<td>0</td>
<td>–</td>
<td>8.3</td>
</tr>
<tr>
<td></td>
<td>BRV 200 (249)</td>
<td>66.8</td>
<td>44.4</td>
<td>16.8</td>
<td>8</td>
<td>14.4</td>
<td>11.6</td>
<td>11.2</td>
<td>3.2</td>
<td>2</td>
<td>0</td>
<td>6.8</td>
</tr>
<tr>
<td>Toledo et al&lt;sup&gt;76&lt;/sup&gt; (LTFU)</td>
<td>BRV overall (2,186)</td>
<td>84.5</td>
<td>54.2</td>
<td>15.2</td>
<td>20.9</td>
<td>17.5</td>
<td>11.3</td>
<td>–</td>
<td>18.3</td>
<td>28</td>
<td>4</td>
<td>12.1</td>
</tr>
<tr>
<td></td>
<td>BRV 50 (319)</td>
<td>86.8</td>
<td>64.3</td>
<td>16.6</td>
<td>24.8</td>
<td>19.7</td>
<td>11.6</td>
<td>–</td>
<td>20.7</td>
<td>7</td>
<td>3</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>BRV 100 (544)</td>
<td>86.2</td>
<td>58.3</td>
<td>18</td>
<td>21.9</td>
<td>16.5</td>
<td>10.7</td>
<td>–</td>
<td>19.5</td>
<td>10</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>BRV 150 (869)</td>
<td>86.3</td>
<td>54.7</td>
<td>13.8</td>
<td>22.6</td>
<td>18.3</td>
<td>11.6</td>
<td>–</td>
<td>19.3</td>
<td>9</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>BRV 200 (454)</td>
<td>77.5</td>
<td>41.2</td>
<td>13.7</td>
<td>13.9</td>
<td>15.4</td>
<td>11.2</td>
<td>–</td>
<td>13.4</td>
<td>2</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

**Abbreviations:** AEs, adverse events; BRV, brivaracetam; LTFU, long-term follow-up; PBO, placebo; SAEs, serious AEs; TEAEs, treatment-emergent AEs.
and 1.9% for depression. The TEAEs significantly related to BRV were irritability, fatigue, somnolence and dizziness. Irritability, insomnia, depression and anxiety, which were the most commonly described psychiatric AEs, occurred in 2% to almost 3% of the BRV-treated participants. No clinically significant modifications from baseline were reported in blood chemistry, urinary parameters, vital signs, electrocardiogram (ECG) findings and physical and neurological examination. Four participants died during two trials. The first patient, who was receiving BRV 50 mg/day, died 2 weeks after he had discontinued the drug because of a subarachnoid hemorrhage, while another participant, taking BRV 20 mg/day, had a cardiorespiratory arrest following an epileptic crisis. Two more participants died, while receiving BRV 200 mg/day; one death was unexplained and the other one died during an epileptic attack. However, no deaths were judged by investigators to be BRV treatment related.

Long-term extension studies
Data deriving from a pooled analysis including Phase IIb, Phase III and associated LTFU studies were consistent with those reported earlier. More in detail, 1,848 (84.5%) out of 2,186 patients treated with BRV 50–200 mg/day, experienced at least one TEAE, which was considered to be drug related in 1,184 (54.2%). There was no evidence that TEAE incidence was dose dependent. The most common TEAE for BRV 50–150 mg/day was headache (13.9%–24.8%); for BRV 200 mg/day it was dizziness (15.4%). Other TEAEs (dizziness, somnolence, nasopharyngitis, fatigue and epilepsy) occurred in 10% of the treated population. Of 2,186 patients, 264 (12.1%) were forced to discontinue treatment because of TEAEs (convulsions 1.4%, pregnancy 0.9%, somnolence 0.7%, depression 0.6%, dizziness 0.6%, fatigue 0.5%, suicide ideation 0.5% and suicide attempt 0.5%). The most common psychiatric AEs were depression (7.1%), insomnia (6.2%), irritability (5.2%), anxiety (4.9%), suicide ideation (2.0%), depressed mood (1.8%), aggression (1.7%), nervousness (1.6%) and sleep disorders (1.6%). Serious AEs (SAEs) occurred in 401 (18.3%) patients and resulted to be treatment related in 95 (4.3%). Of the 28 deaths reported (1.3%), four could be possibly related to drug therapy. Two patients, aged 30 and 50 years, experienced a sudden unexpected death in epilepsy (SUDEP) while receiving BRV 50 mg/day for 8.2 and 42.2 months, respectively. A potential SUDEP event was described also for a young woman aged 21 years, who was taking BRV 50 mg/day when brain hypoxia occurred. Finally, a 20-year-old man committed suicide after a 24.8-month treatment period with BRV 150 mg/day. To date, no evident idiosyncratic AEs have been identified.

Results from LTFU studies relative to seizure outcome and safety and tolerability are summarized in Table 3A and B.

**BRV IV formulation**
Recently, a Phase III, randomized trial was conducted to assess the safety and tolerability of add-on BRV as IV infusion or bolus in patients affected by epilepsy. The study, involving 105 adults aged 16–70 years with focal or generalized epilepsy, comprised a baseline period of 7 days, followed by a 7-day double-blind run-in period, in which patients received oral BRV 200 mg/day or PBO. Finally, participants underwent a 4.5-day open-label evaluation period in which they received IV BRV, administered as a 15-min infusion or 2-min bolus at 100 mg twice daily, for nine doses. Patients were randomized to receive PBO/BRV bolus, PBO/BRV infusion, BRV/BRV bolus and BRV/BRV infusion. Participants who completed the study were offered entry into an LTFU study or down-titration. A similar incidence of TEAE was reported for each treatment arm. No relevant differences were noted in TEAE incidence for IV BRV used de novo (after PBO – initiation group) or as replacement for oral administration (after oral BRV – conversion group). The same incidence of AEs was reported also for IV BRV administered as bolus or infusion. The most frequently described AEs were somnolence (29.5%) and dizziness (14.3%), with somnolence being the most common drug-related TEAE. Severe TEAEs (nausea, vertigo) occurred only in one patient

---

**Table 3A** Seizure outcomes from LTFU studies

<table>
<thead>
<tr>
<th>Seizure outcome</th>
<th>1–3 months</th>
<th>58–60 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median percentage reduction from baseline in POS/28 days</td>
<td>43.1%</td>
<td>77.0%</td>
</tr>
<tr>
<td>≥50% responder rate</td>
<td>43.5%</td>
<td>71%</td>
</tr>
<tr>
<td>6 months</td>
<td>4.9%</td>
<td>4.2%</td>
</tr>
<tr>
<td>12 months</td>
<td>3.0%</td>
<td>3.3%</td>
</tr>
<tr>
<td>24 months</td>
<td>68.1%</td>
<td>54.4%</td>
</tr>
<tr>
<td>60 months</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Exposure time to BRV modal dose 50–200 mg/day.

**Abbreviations:** BRV, brivaracetam; LTFU, long-term follow-up; POS, partial-onset seizure.
and were considered to be drug related. There were no serious TEAEs, and no deaths were reported. Two patients interrupted the trial: one patient in the PBO/BRV bolus arm because of rash occurring during the run-in period, before receiving any dose of BRV. The other patient belonged to PBO/BRV infusion arm; after he had received six doses of BRV, he was forced to discontinue the treatment because of anxiety. Injection-related TEAEs during the IV BRV period occurred with a low frequency for both bolus and infusion groups (9.6 and 11.5%, respectively) and consisted of erythema, injection/infusion-site pain. They never required treatment discontinuation.

Table 4 summarizes differences and similarities of the main trials on LCM, PER, ESL and BRV.

### Patient-focused perspectives

One of the most important goals of the epilepsy management is to achieve seizure freedom, but health-related quality of life (HRQoL) is also important and should be considered a crucial aspect in the evaluation of treatment success.
Table 4 Comparison of ≥50% responder rate, seizure-free percentage, and TEAEs between LCM, ESL, BRV, and PER

<table>
<thead>
<tr>
<th>AED</th>
<th>RCTs</th>
<th>ITT</th>
<th>Treatment dose (mg/day) and number of patients</th>
<th>≥50% responder rate</th>
<th>Seizure freedom (%)</th>
<th>TEAEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>LCM</td>
<td>Halasz et al⁷⁹ 485</td>
<td>200 (160)</td>
<td>35.0 (200 mg)</td>
<td>3.6 (200 mg)</td>
<td>96/163 (200 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chung et al⁸⁰ 405</td>
<td>400 (158)</td>
<td>40.5 (400 mg)</td>
<td>2.4 (400 mg)</td>
<td>116/159 (400 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>400 (104)</td>
<td>25.8 (PBO)</td>
<td>25.8 (PBO)</td>
<td>43/163 (PBO)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>600 (97)</td>
<td>38.3 (400 mg)</td>
<td>2.5 (400 mg)</td>
<td>42.0 (400 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PBO (104)</td>
<td>41.2 (600 mg)</td>
<td>8.1 (600 mg)</td>
<td>50.0 (600 mg)</td>
<td></td>
</tr>
<tr>
<td>ESL</td>
<td>Elger et al⁸¹ 295</td>
<td>400 (100)</td>
<td>23</td>
<td>16.7 (400 mg)</td>
<td>44.0 (ESL 400 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>800 (98)</td>
<td>34</td>
<td>40.05 (800 mg)</td>
<td>50.0 (ESL 800 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1,200 (102)</td>
<td>47</td>
<td>37.6 (1,200 mg)</td>
<td>60.8 (ESL 1,200 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PBO (102)</td>
<td>20</td>
<td>12.0 (PBO)</td>
<td>31.4 (PBO)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sperling et al⁸² 640</td>
<td>800 (215)</td>
<td>30.5</td>
<td>30.5 (800 mg)</td>
<td>67.1 (800 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1,200 (205)</td>
<td>42.5</td>
<td>42.6 (1,200 mg)</td>
<td>77.6 (1,200 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PBO (220)</td>
<td>23.1</td>
<td>23.1 (PBO)</td>
<td>55.8 (PBO)</td>
<td></td>
</tr>
<tr>
<td>BRV</td>
<td>Kwan et al⁸³ 480</td>
<td>BRV 20–150 (359)</td>
<td>32.0 (5 mg)</td>
<td>8.0 (5)</td>
<td>66.0 (BRV)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PBO (121)</td>
<td>44.2 (20 mg)</td>
<td>7.7 (20)</td>
<td>65.3 (PBO)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>55.8 (50 mg)</td>
<td>7.7 (50)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>16.7 (PBO)</td>
<td>1.9 (PBO)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ryvlin et al⁸⁴ 398</td>
<td>BRV 20 (99)</td>
<td>20</td>
<td>0</td>
<td>56.6 (BRV 20 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>BRV 50 (99)</td>
<td>27.3</td>
<td>2</td>
<td>62.6 (BRV 50 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>BRV 100 (100)</td>
<td>27.3</td>
<td>2</td>
<td>63.0 (BRV 100 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Klein et al⁸⁵ 760</td>
<td>PBO (259)</td>
<td>21.6</td>
<td>0.8</td>
<td>67.6 (BRV)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>BRV 100 (252)</td>
<td>38.9</td>
<td>5.2</td>
<td>59.4 (PBO)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>BRV 200 (249)</td>
<td>37.8</td>
<td>4</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>PER</td>
<td>Steinhoff et al⁸⁶ 1,480</td>
<td>2, 4, 8 or 12 mg/day (1,038)</td>
<td>28.5 (4 mg)</td>
<td>4.4 (4 mg)</td>
<td>77.5 (PER)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PBO (442)</td>
<td>35.3 (8 mg)</td>
<td>3.5 (8 mg)</td>
<td>66.5 (PBO)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>35.0 (12 mg)</td>
<td>4.1 (12 mg)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>19.3 (PBO)</td>
<td>1.0 (PBO)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lagae et al⁸⁷ 133</td>
<td>Up to 12 mg/day (85 PBO [48])</td>
<td>59.0 (PER)</td>
<td>23.7 (PER)</td>
<td>68.2 (PER)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>16.3 (PBO)</td>
<td>16.3 (PBO)</td>
<td>41.7 (PBO)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BRV, brivaracetam; ESL, eslicarbazepine; ITT, intention-to-treat; LCM, lacosamide; PBO, placebo; PER, perampanel; RCTs, randomized controlled trials; TEAE, treatment-emergent adverse effect; AED, antiepileptic drug.

Variables influencing HRQoL are TEAE rate due to antiepileptic therapy, depression, anxiety, perceived stigma of epilepsy and consequent lack of independence. In this regard, HRQoL was assessed in a large pooled analysis⁷⁷ including patients from Phase IIb, III and LTFU studies, using the Quality of Life in Epilepsy Inventory-31 (QOLIE-31P), a patient-reported instrument evaluating seven subscales. In the efficacy population (BRV modal doses 50–200 mg/day, n=1,836), improvements in HRQoL were reported in 45% of patients from baseline in 59 and 55% of patients, respectively. Lower improvements were observed at subsequent time points (eg, month 48), probably due to a change in population composition, which became more heterogeneous with respect to the original core studies, and a reduced patient number. In fact, at month 42, the majority of the population consisted of patients who responded well to BRV and continued to LTFU studies; while, over time, a critically lower number of patients was available for HRQoL assessments, due to protocol-specified completion of QOLIE-31P which was limited to 24 months for patients enrolled later. A meaningful improvement in daily activities/social functioning was observed during ≥42 months of BRV administration. Overall data confirm a sustained effect of BRV, used as long-term (≥8 years) treatment, in improving HRQoL without any deterioration in safety and tolerability.

According to these data, adjunctive BRV in adults showed high adherence to treatment over time; in fact, patients from core and LTFU studies receiving BRV 50–200 mg/day showed retention rates of 91.0, 79.8, 68.1 and 54.4% at month 6, 12, 24 and 60, respectively.⁷⁶

**Most appropriate patient profiles for treatment with BRV**

Adjunctive BRV proved to be effective in reducing seizure frequency in adults aged 16–80 years with POS at the dose...
range of 50–200 mg/day, in Phase IIb, Phase III and LTFU studies. On the other hand, BRV seems to provide no additional benefit when administered with concomitant LEV, probably due to competition for the same binding sites. Nevertheless, BRV was able to provide good results in patients who previously discontinued LEV because of TEAEs, rather than due to lack of efficacy. In fact, as reported in a small Phase III study including adults with refractory epilepsy, a decrease in behavioral AE rate was observed when patients switched from LEV to BRV.77

Overall, BRV showed a favorable safety and tolerability profile as supported by high retention rates across all BRV doses, and low incidence of TEAEs, which were of mild-to-moderate intensity. No idiosyncratic AEs were reported. BRV tolerability, safety and efficacy were assessed in a pooled analysis involving patients aged ≥65 years from the three fixed-dose Phase III studies, showing results consistent with those observed in larger populations mentioned earlier and, therefore, suggesting that BRV is a suitable add-on treatment also in the elderly.78

Recently, the efficacy, tolerability and safety of add-on BRV have been investigated in adult patients with Unverricht–Lundborg disease in two prospective, double-blind, Phase III trials,60 in which patients were randomized to receive BRV or PBO; these studies failed to show a statistically significant effect of adjunctive BRV on action myoclonus score compared to PBO.

Interestingly, thanks to its rapid predicted blood–brain permeability and fast brain SV2A occupancy observed in preclinical studies,61 IV BRV formulation may have a role in the treatment of emergency situations, such as status epilepticus. However, as yet, there is no experience in this field.

To date, BRV has not yet been evaluated as monotherapy or in comparison with other new AEDs, neither during pregnancy nor during lactation. Concerning children, there is an ongoing Phase III study whose results are still unpublished.

**Place in therapy and conclusion**

BRV was approved in the EU in January 2016 and in the US in February 2016 as adjunctive therapy for the treatment of POS in patients older than 16 years of age.60 Hence, it is undoubtedly a drug included among the therapeutic options for partial seizures both as adjunctive therapy and, likely, as monotherapy. However, its place in therapy remains to be defined due to the lack of head-to-head clinical studies comparing BRV with other AEDs and to the need for broader real-world clinical experience. Thanks to a low incidence of TEAEs and idiosyncratic adverse effects, BRV seems a suitable add-on treatment also for the elderly.

The IV BRV formulation could be suitable for the treatment of emergency situations, such as status epilepticus. However, as yet, there is no experience in this field.

Finally, it could be considered as a potential alternative to LEV in the presence of adverse effects, especially behavioral side effects. Pediatric clinical data with BRV are expected within the next year.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 02-Sep-2018
For personal use only.